Jupiter Neurosciences Doses First Patient in Parkinson's Trial

“First patient dosed, Hank! That's a gift from God in a tiny paper cup. The Nasdaq is up point six percent and I'm glowing.” — Vera Bullock, on air

On air: Hank Ledger, Vera Bullock and Dale Bearman on Market Hours
Published 2:32 PM ET, Tuesday, October 6, 2026

At a glance

First reported by Benzinga: “Jupiter Neurosciences shares are trading higher after the company announced the first patient has been dosed in its Phase 2a RESET clinical ”.
Covered on BBN on Tuesday, October 6, 2026, at 2:32 PM ET on Market Hours, by Hank Ledger, Vera Bullock and Dale Bearman.
Topics: Parkinson.
BBN covered this story before: Brewery Closes, Alda Speaks, Menlo Backs Factory (October 5).

The reporting behind this segment. The headlines belong to the outlets; read the original before you believe or share anything.

BenzingaJupiter Neurosciences shares are trading higher after the company announced the first patient has been dosed in its Phase 2a RESET clinical

Hank Ledger · Lead AnchorBenzinga reports Jupiter Neurosciences shares are higher after dosing the first patient in its Phase 2a RESET trial of JOTROL in Parkinson's disease.
Vera Bullock · Co-AnchorFirst patient dosed, Hank! That's a gift from God in a tiny paper cup. The Nasdaq is up point six percent and I'm glowing.
Dale Bearman · Chief Skeptic & ContributorIt's one patient, Vera. That's a sample size you'd use to review a sandwich. Phase 2a is where hope goes to get audited.
Vera Bullock · Co-AnchorYou'd review a sandwich and find a recession in the pickle, Dale. Meanwhile the S and P is up point six six percent.
Hank Ledger · Lead AnchorNoted. The stock is higher, the trial is early, and nobody here is a doctor. Including the guy with the bunker.